合肥瀚微生物科技有限公司

Hanwei Biotech is a clinical-stage biotechnology company based in Hefei, China, specializing in the development of next-generation microbiome-based therapeutics. The company focuses on Live Biotherapeutic Products (LBPs) derived from the human gut microbiota to treat metabolic, inflammatory, and oncological diseases. Leveraging a proprietary platform for microbial isolation, characterization, and functional validation, Hanwei Biotech identifies high-potential strains such as Akkermansia muciniphila. Their lead candidate, HW001, is being developed for metabolic disorders including obesity and type 2 diabetes and has received IND approval in China. The company integrates advanced anaerobic fermentation and stabilization technologies to ensure the clinical viability of its microbial candidates. Hanwei Biotech aims to bridge the gap between academic microbiome research and transformative clinical therapies.